

DATE:1	11 May 2026
TO:	North Zone, Edmonton Zone and Central Zone
FROM:	Clinical Biochemistry – North Sector
RE:	Urine Toxicology Panels - University of Alberta Hospital - Toxicology Laboratory

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Four (4) new analytes have been added to both the Urine General Toxicology Panel (UGTP) and the Urine Opioid Dependency Panel (UODP):
 - 3-hydroxymedetomidine (metabolite of medetomidine)
 - 3-hydroxydesalkylgidazepam (metabolite of desalkylgidazepam – a novel benzodiazepine; desalkylgidazepam is also a metabolite of gidazepam)
 - alpha-hydroxyflubromazolam (metabolite of flubromazolam - a novel benzodiazepine)
 - 3-hydroxyflubromazepam (metabolite of flubromazepam - a novel benzodiazepine)
- In addition, the following three (3) analytes will be deleted from the panels:
 - Flubromazolam will be removed from both the UGTP and the UODP and replaced with alpha-hydroxyflubromazolam as noted above.
 - Flubromazepam will be removed from both the UGTP and the UODP and replaced with 3-hydroxyflubromazepam as noted above.
 - para-methoxymethamphetamine will be removed from the UGTP. This analyte is being removed as it no longer appears in the drug supply. Requests for this analyte can be accommodated on a case by case basis.

Background

- Analytes are added to and removed from the panels to ensure they remain relevant.

How this will impact you

- These four (4) new analytes may be reported on samples submitted for qualitative toxicology testing.

Action Required

- Be aware of the changes in analytes detected by these two (2) drug testing panels. Continue to request the UGTP **or** UODP on your patient as required.
- As a reminder the UGTP and the UODP have a high degree of drug overlap. The UODP is intended for patients in opioid agonist therapy programs and the UGTP is for general assessment (including pain management, psychiatry, general addiction, etc.). **Order ONLY ONE of the two test panels.** For a complete list of drugs in each panel, along with current cut-off concentrations, visit <https://www.albertahealthservices.ca/assets/wf/lab/if-lab-toxicology-drug-testing-panels.pdf>

Effective 19 May 2026

Questions/Concerns

- Dr. Penny Colbourne, Clinical Toxicologist, 780-407-4729

Approved by

- Dr. Kareena Schnabl, Section Chief Biochemistry, North Sector
- Dr. Michael Mengel, Medical Director, North Sector